AASLD – The Liver Meeting 2019

infohep news

• Hepatocellular carcinoma (HCC)

  A healthy lifestyle could prevent most liver cancer and liver-related deaths

  Liz Highleyman / 17 December 2019

  A healthy lifestyle, including smoking cessation, moderate drinking, a balanced diet, exercise and weight loss could dramatically reduce the growing burden of liver cancer and deaths due to liver disease, according to a study ...

• Hepatitis delta

  Combination therapies show promise against hepatitis D

  Liz Highleyman / 16 December 2019

  Combination regimens using lonafarnib or bulevirtide reduced levels of hepatitis delta virus (HDV) in a majority of people with HDV and hepatitis B virus (HBV) co-infection, researchers reported at the AASLD Liver Meeting ...

• NAFLD

  Global burden of deaths and liver cancer due to non-alcoholic fatty liver disease growing

  Keith Alcorn / 11 December 2019

  Non-alcoholic fatty liver disease is a growing cause of liver cancer and death in some regions of the world, an analysis of global reporting on liver disease shows. The findings ...

• Hepatocellular carcinoma (HCC)

  Immunotherapy combination improves liver cancer survival

  Liz Highleyman / 27 November 2019

  A combination of nivolumab (Opdivo) and ipilimumab (Yervoy), two different types of checkpoint inhibitor immunotherapy, led to higher response rates and longer survival than nivolumab alone in people with advanced liver cancer, according to a ...

• Experimental treatments for NASH/NAFLD

  New NASH therapies show promise in mid-stage studies

  Liz Highleyman / 26 November 2019

  Phase II study results presented at the AASLD Liver Meeting this month in Boston show that a number of experimental therapies improve markers of liver health in people with non-alcoholic steatohepatitis (NASH). ...

• NAFLD

  People with fatty liver disease struggle to lose weight

  Liz Highleyman / 25 November 2019

  Losing weight may be especially difficult for people with fatty liver disease due to differences in their metabolism. But nonetheless, some can succeed and doing so improves liver health, according to studies ...

• Hepatocellular carcinoma (HCC)

  Sustained response to HCV antivirals boosts liver cancer survival

  Liz Highleyman / 19 November 2019

  People with liver cancer who achieved a sustained virological response (SVR) to direct-acting antiviral (DAA) therapy for hepatitis C saw a reduction in both liver-related and all-cause mortality over five years, according to ...

• Hepatocellular carcinoma (HCC)

  Hepatitis B antiviral drugs reduce liver cancer risk

  Liz Highleyman / 19 November 2019

  Treating hepatitis B virus (HBV) with nucleoside/nucleotide antiviral drugs was associated with a lower risk of developing hepatocellular carcinoma (HCC), the most common type of liver cancer, according to studies presented last week ...

• Sexual transmission

  Hepatitis C incidence is low among Canadian men on PrEP

  Liz Highleyman / 18 November 2019

  New cases of hepatitis C virus (HCV) infection among Canadian gay and bisexual men taking pre-exposure prophylaxis (PrEP) were uncommon compared with rates previously reported in Europe, according to research ...

• Transplants from donors with HCV

  Pre- and post-transplant antiviral treatment prevents hepatitis C transmission in all organ recipients, Canadian study finds

  Keith Alcorn / 14 November 2019

  Adding a cholesterol-lowering drug to direct-acting antivirals (DAAs) prevented hepatitis C infection in all recipients of organ transplants from donors with hepatitis C, Jordan Feld, Research Director of the Toronto Centre for ...